Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.
Circio has raised $31.5M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Circio's investors include Innovation Norway, Birk Venture, Radium Hospital Research Foundation, Atlas Special Opportunities, Algot Invest.
Circio is headquartered in Oslo, Norway.
Targovax develops active immunotherapy in the form of cancer vaccines for application in post-operation treatments.
Circio is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Circio — Funding & Investors." VCBacked, June 10, 2026, https://www.vcbacked.co/company/circio. Accessed October 7, 2026.
VCBacked. (2026). Circio — Funding & Investors. Retrieved October 7, 2026, from https://www.vcbacked.co/company/circio
{{cite web |title=Circio — Funding & Investors |url=https://www.vcbacked.co/company/circio |website=VCBacked |access-date=October 7, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated